Run the group — the value-added & specialty mix shift, Asepto's scale-up (12→24 bn packs with Egypt), the films-cycle recovery (Q4 exit 15.3%), circularity leadership, and capital allocation & deleverage across the four businesses.
filtered to your role
The UFlex thesis: shift the mix from cyclical commodity films to value-added — Asepto, specialty & PCR — the four pillars, the value levers, how the group is performing, the P&L & cash, the margin journey by business, and the shareholder value it creates.
The cockpit panes for your role — one click in.
The biggest shifts across the business.